- Choong, Grace, M.D., Mayo Clinic Rochester, USA, Charité-Mayo-Conference distilled 2024, What is the Best Therapy for Relapsed Endometrial Cancer? Chemotherapy Pretreated or Naïve?, 13.04.2024
In general, recurrent endometrial cancer is associated with a 5-year survival rate of around 20 to 25 per cent. However, new studies suggest more favourable outcomes as a result of improved treatment options, which may lead to a longer PFS and longer survival times.
There are various treatment approaches for patients with recurrent endometrial cancer:
If the patient has already undergone platinum-containing chemotherapy and recurrences still occur, the procedure changes slightly.
There are updated treatment recommendations for patients with recurrent endometrial cancer. Depending on the receptor status and previous therapy, there are different treatment paths. In general, patients should also be included in clinical trials where possible. The overall prognosis is still rather negative, but new therapeutic approaches offer improved outcomes in terms of PFS and OS.